Marchés français ouverture 5 h 58 min
Dow Jones
38 460,92 -42,77 (-0,11 %) Nasdaq
15 712,75 +16,11 (+0,10 %) Nikkei 225
37 992,09 -467,99 (-1,22 %) EUR/USD
1,0707 +0,0006 (+0,05 %) HANG SENG
17 201,27 +372,34 (+2,21 %) Bitcoin EUR
60 308,87 -2 052,79 (-3,29 %)
Lexaria Bioscience Corp. (LEXXW)
NasdaqCM - NasdaqCM Prix différé. Devise en USD
Ajouter à la liste dynamique
À la clôture : 04:00PM EDT
| Clôture précédente | 0,7600 |
| Ouverture | 0,7300 |
| Offre | 0,0000 x 0 |
| Vente | 0,0000 x 0 |
| Var. jour | 0,5111 - 0,7500 |
| Sur 52 semaines | 0,5111 - 0,7500 |
| Volume | |
| Volume moyen | S.O. |
| Cap. boursière | S.O. |
| Bêta (mensuel sur 5 ans) | 0,95 |
| Rapport P/E (sur 12 mois) | S.O. |
| BPA (sur 12 mois) | S.O. |
| Date de bénéfices | S.O. |
| Dividende et rendement à terme | S.O. (S.O.) |
| Date ex-dividende | S.O. |
| Objectif sur 1 an | S.O. |
ACCESSWIRELexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,
